Navigation Links
Neurogen Proprietary Insomnia Compound Data Presented at American,Psychiatric Association Annual Meeting

BRANFORD, Conn.--(BUSINESS WIRE)--May 23, 2007 - Neurogen Corporation (Nasdaq: NRGN) today announced that data from previous Phase 1 and Phase 2a clinical studies for NG2-73, the Company's lead compound for the treatment of insomnia, were presented today at the American Psychiatric Association (APA) annual meeting in San Diego. Two Phase 2b clinical studies with NG2-73 in chronic insomnia patients are currently being conducted by the Company. Data presented at the APA meeting include the following abstracts:

--NG2-73, a Novel GABA(A) Partial Agonist, Rapidly Induced Sleep in a Transient Insomnia Study (Phase 2a)

NG2-73 is a partial GABA(A) agonist with preference for receptors containing the (alpha)3 subunit. Preclinical studies suggest that this compound has sedative hypnotic effects, supporting development as a potential treatment for insomnia.

This double-blind, placebo-controlled, randomized, multi-center study was designed to determine the effects of 1,3,10 and 20mg of NG2-73 compared to placebo on sleep onset as measured by Latency to Persistent Sleep (LPS) in healthy adults. The study design incorporated a single-night, polysomnography (PSG) model of transient insomnia using both first night sleep laboratory adaptation and "phase-advance" effects. Subjects were dosed in the sleep laboratory 2.5 hours prior to median habitual bedtime. "Lights off" and PSG recording started 30 minutes later. Safety was monitored by adverse event recording, physical exams, vital signs, electrocardiogram (ECG) and clinical laboratory tests. 369 healthy subjects aged 24-63 with no self-reported sleep disorders were enrolled.

LPS was statistically significantly reduced, compared to placebo, at all doses of NG2-73, and demonstrated a dose-response relationship. The mean times for LPS were 30.8 minutes for the Placebo group, and 17.8, 10.6, 7.8, and 6.6 minutes for the 1, 3, 10, and 20 mg NG2-73 groups, resp
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials
2. Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting
3. Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting
4. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
5. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
6. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
7. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
8. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
9. Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention
10. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
11. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
Post Your Comments:
(Date:9/16/2014)... and BOSTON , September 16, ... Chief Scientific Officer, Fiona Marshall , will give a ... G protein-coupled receptors using StaR ®   ... Advances in Drug Discovery and Development " virtual symposium run ... Chemical Society. The virtual symposium is on Wednesday, 24 September ...
(Date:9/15/2014)... , Sept. 16, 2014  Bayer HealthCare ... Espoo, Finland , have begun ... with ODM-201, an investigational oral androgen receptor inhibitor ... ODM-201 in men with castration-resistant prostate cancer who ... no detectable metastases. The trial is designed to ...
(Date:9/15/2014)... 15, 2014 GenomeDx Biosciences today announced ... American Society for Radiation Oncology (ASTRO) Annual Meeting ... Classifier, a genomic test capable of predicting aggressiveness ... improve patient outcomes for prostate cancer patients following ... recently published study that demonstrates how Decipher test ...
Breaking Medicine Technology:Heptares to Present on Structure-Based Drug Design Using G Protein-Coupled Receptors at Inaugural Chemistry & Engineering News Virtual Symposium 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 3Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 2Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 3
... SILVER SPRING, Md., July 1, 2011 The ... Neohaler (indacaterol inhalation powder) for the long term, ... people with chronic obstructive pulmonary disease (COPD) including ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) COPD is a ...
... DUBLIN, July 1, 2011 ,   ... SHPGY ), the global specialty,biopharmaceutical company, announces that it ... District of New Jersey against each,of Amneal Pharmaceuticals, LLC ... Shire,s VYVANSE,patents. The lawsuits were initiated in ...
Cached Medicine Technology:FDA Approves Arcapta Neohaler to Treat Chronic Obstructive Pulmonary Disease 2Shire Files Lawsuits Against Sandoz and Amneal for Infringement of VYVANSE® (lisdexamfetamine dimesylate) Patents 2
(Date:9/16/2014)... September 16, 2014 A recent ... used as a dermal filler, “Expression”, which has not ... on the market to be used as an intra-nasal ... FDA for use as a dermal filler. Because of ... off-label for wrinkle reduction, and patients have had bad ...
(Date:9/16/2014)... September 16, 2014 Dr. Eric Millstein ... of ACLsurgeryLA.com , a specialty website devoted to ... As an avid sports lover and athlete, Dr. Millstein ... and recovery from injuries to maintain active, healthy lifestyles. ... patients a resource dedicated specifically to ACL injuries ...
(Date:9/16/2014)... OXNARD, CA (PRWEB) September 16, 2014 ... Jivraj, founder of the Anacapa Dental Art Institute in ... Spectrum Day Vancouver conference this weekend. , Dr. Jivraj, ... about All-on-4™ dental implants in his presentation ... he will deliver at 12:40 p.m. Saturday, Sept. 20, ...
(Date:9/16/2014)... 2014 MEDICC Review today ... genetics in Cuba. Although the articles do not ... are intrinsically connected, since cancers begin with errors in ... full spectrum of cancer control, from primary prevention to ... topic of an exclusive interview with National Medical ...
(Date:9/16/2014)... NY (PRWEB) September 16, 2014 Registration ... Run For The Warriors®, a 10K, 5K, and 1-mile ... The race is sponsored by Local 338 RWDSU/UFCW, the ... will begin at the Town of Babylon Town Hall ... http://www.hopeforthewarriors.org/2014LIRun . The run is organized by Hope ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Non-approved Dermal Filler 2Health News:FDA Warns Against Non-approved Dermal Filler 3Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 2Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 3Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 2Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 3Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 4Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 5Health News:MEDICC Review Journal Dedicates Double Issue to Cancer and Genetics 2Health News:MEDICC Review Journal Dedicates Double Issue to Cancer and Genetics 3Health News:The Hope For The Warriors Long Island Run For The Warriors to Honor Wounded and Families of the Fallen 2
... of,Public Welfare said today it is working with ... an abandoned child in,Lansdowne, Delaware County., An ... noon today and said, "I left a baby ... without providing any other information. Local law,enforcement was ...
... and large numbers of men, are interested in having cosmetic ... Journal of Plastic and Reconstructive Surgery. , ... in cosmetic surgery, liposuction or both, and another 23 percent ... Among men, 23 percent said they would be interested in ...
... /PRNewswire/ - The IND proposes a randomized Phase,III ... Best Supportive,Care (BSC) versus BSC alone for the ... gastroesophageal junction and stomach who,have failed adjuvant or ... of the IND and will direct the clinical ...
... Oct. 26 In a statewide,effort to help ... violence shelters, the Michigan State Medical Society (MSMS),Foundation ... and,distribute personal care items in conjunction with the ... Day" on,Saturday, October 27., "The women and ...
... WHEATON, Ill., Oct. 26 The following is a,media ... Rehabilitation Hospital is the 2007 recipient of the,James Brady ... or organization,that goes above and beyond to improve lives ... goals of the Brain Injury Association of,Illinois., In ...
... UniCare announced today a policy to,make it easy for ... the prescription drugs they need. A one-time override ... up so,that UniCare policyholders in the affected counties can ... in place for,members living in Los Angeles, Orange, San ...
Cached Medicine News:Health News:Safe Haven Hotline Receives Report of Abandoned Baby in Lansdowne 2Health News:Huge numbers willing to go under knife to alter their appearance, study finds 2Health News:Supratek Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SP1049C for the treatment of metastatic adenocarcinoma of the upper gastrointestinal tract 2Health News:Michigan State Medical Society Foundation 'Makes A Difference' by Assisting Those in Crisis Shelters 2Health News:Marianjoy Rehabilitation Hospital to Receive James Brady Award From Brain Injury Association of Illinois 2Health News:UniCare Announces Temporary Pharmacy Guidelines for Customers Affected by the California Wildfires 2
3.2% Tryptone, 2.0% Yeast Extract, 0.5% Sodium Chloride, pH 7.5....
... radial head system employs the advantages of ... create the next generation of modular radial ... modular design, the implant system offers the ... patients anatomy. In addition, the capability of ...
For connection to the bipolar output of electrosurgical generators....
Recommended for use with spark gap coagulators for added safety. Also available in stainless steel (10-3002)....
Medicine Products: